Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Infusion preparation for dialysis patient

A technology for patients and uses, applied in blood diseases, drug delivery, extracellular fluid diseases, etc., to achieve the effect of reducing the dosage and frequency of occurrence

Inactive Publication Date: 2012-07-25
AJINOMOTO CO INC
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] Although a variety of amino acid preparations are available for patients with renal failure, there are no literature or reports describing the use of these drugs to control serum phosphorus levels in appropriate ranges in dialysis patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Infusion preparation for dialysis patient
  • Infusion preparation for dialysis patient
  • Infusion preparation for dialysis patient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] Embodiment 1: Preparation of anti-anemia preparation (amino acid infusion)

[0091] The ingredients shown in the following Table 1 were dissolved in water for injection according to the amounts shown in the table. The solution was sterile filtered and placed in a glass bottle. The bottle was sealed and autoclaved to prepare an anti-anemia preparation (amino acid infusion).

[0092] The pH value of the preparation is 6.6-7.6, and the osmotic pressure ratio is about 2.

[0093] Table 1:

[0094] Element

[0095] The amino acid infusion prepared according to Example 1 is also used as the following purposes: a pharmaceutical preparation for reducing the dosage of erythropoietin (second aspect of the present invention), a pharmaceutical preparation for controlling serum phosphorus levels (third aspect of the present invention) and Pharmaceutical preparations for inhibiting protein catabolism (fourth aspect of the invention).

Embodiment 2

[0096] Example 2. Determination of the ability of pharmaceutical preparations to improve anemia and reduce the dosage of erythropoietin

[0097] Exemplary anti-anemia preparation of the present invention was administered to 18 chronic renal failure patients receiving hemodialysis (HD: 9 cases) or hemodiafiltration (HFD: 9 cases) to examine that the preparation improves anemia and reduces erythropoietin administration Quantitative capacity.

[0098] [method]

[0099] A commercially available amino acid infusion solution "NEOAMYU (registered trademark)" (200 mL formulation, Ajinomoto Pharma Co., Ltd.) prepared according to Example 1 was used.

[0100] In the week before the administration period, the necessary diagnosis, examination and detection were carried out on the first dialysis day (week 1 or week 2). The "NEOAMYU" preparation was continuously administered from 1 week after the diagnosis to 12 weeks and 1 day (the 37th dialysis). Specifically, 1 vial (200 mL) of the pr...

Embodiment 3

[0107] Example 3: Determination of the ability of the above pharmaceutical formulations to control serum phosphorus levels

[0108] The exemplary serum phosphorus control preparation of the present invention was administered to 8 chronic renal failure patients receiving hemodialysis (HD) to examine changes in serum phosphorus levels.

[0109] [method]

[0110] The commercially available amino acid infusion solution "NEOAMYU" (200 mL formulation, Ajinomoto Pharma Co., Ltd.) prepared according to Example 1 was used.

[0111] In the week before the administration period, the necessary diagnosis, examination and detection were carried out on the first dialysis day (week 1 or week 2). The "NEOAMYU" preparation was continuously administered from 1 week after the diagnosis to 12 weeks and 1 day (the 37th dialysis). Specifically, 1 vial (200 mL) of the preparation was infused into the venous side of the dialysis circuit each time of dialysis. The formulation was infused throughout ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An infusion preparation which is to be used in dialyzing a dialysis patient for ameliorating the anemic state by improving nutritional conditions, thus reducing the dosing amount of erythropoietin, controlling the serum phosphorus level to thereby regulate the serum phosphorus level within a definite range and inhibiting the protein catabolism and which contains at least essential amino acids, characterized in that the amino acids are composed of at least L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine, L-arginine, L-aspartic acid, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, glycine and L-cysteine and the ratio of essential amino acids : non-essential amino acids is 2.5 or higher.

Description

[0001] This application is a divisional application based on the application dated June 21, 2007, the application number 200780022937.7, and the title of the invention "transfusion solution for dialysis patients". technical field [0002] The present invention relates to infusion solutions for dialysis patients, and in particular to therapy for anemia in dialysis patients undergoing hemodialysis, hemodiafiltration or other hemodialysis treatments. The present invention also relates to a method for ameliorating anemia in patients with chronic renal failure which entails reducing the amount of erythropoietin (EPO), a hematopoietic hormone administered to patients with chronic renal failure to treat anemia. Background technique [0003] Hemodialysis (HD) is a blood purification technique used to treat patients with chronic renal failure. A challenge with hemodialysis is that it removes not only waste products from the patient's body, but also useful components, such as amino ac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4172A61K31/405A61K31/401A61K31/198A61K31/195A61P3/12A61P7/06
CPCA61K9/0019A61K31/4172A61K31/405A61K31/401A61K31/198A61P3/02A61P3/12A61P7/06
Inventor 杉山隆之
Owner AJINOMOTO CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com